Summit Therapeutics PLC (NASDAQ:SMMT) received a $28.00 price objective from equities research analysts at Canaccord Genuity in a research note issued to investors on Wednesday. The brokerage currently has a a “buy” rating on the stock. Canaccord Genuity’s price objective points to a potential upside of 109.42% from the company’s previous close.
Other equities analysts also recently issued reports about the stock. Janney Montgomery Scott assumed coverage on shares of Summit Therapeutics PLC in a report on Tuesday, June 21st. They issued a “buy” rating on the stock. Oppenheimer Holdings Inc. reissued a “buy” rating on shares of Summit Therapeutics PLC in a report on Thursday, June 16th. Needham & Company LLC boosted their price target on shares of Summit Therapeutics PLC from $22.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday. HC Wainwright assumed coverage on shares of Summit Therapeutics PLC in a report on Friday, September 16th. They issued a “buy” rating and a $26.00 price target on the stock. Finally, Zacks Investment Research raised shares of Summit Therapeutics PLC from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a report on Wednesday, September 14th. Six investment analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average price target of $23.80.
Summit Therapeutics PLC (NASDAQ:SMMT) opened at 13.37 on Wednesday. The company’s market capitalization is $164.37 million. Summit Therapeutics PLC has a 12-month low of $4.26 and a 12-month high of $19.75. The firm has a 50-day moving average of $7.88 and a 200 day moving average of $7.77.
An institutional investor recently raised its position in Summit Therapeutics PLC stock. AXA raised its stake in shares of Summit Therapeutics PLC (NASDAQ:SMMT) by 1.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 382,705 shares of the company’s stock after buying an additional 5,500 shares during the period. AXA owned approximately 3.12% of Summit Therapeutics PLC worth $2,989,000 at the end of the most recent reporting period. 23.43% of the stock is owned by institutional investors and hedge funds.
Summit Therapeutics PLC Company Profile
Summit Therapeutics plc, formerly Summit Corporation plc, is a United Kingdom-based biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. The Company is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Receive News & Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.